Neurology
RSSArticles
-
ECG Review: Early Repolarization or Something More?
-
Clinical Briefs
In this section: potential good cardiovascular news; spironolactone best add-on for resistant hypertension; and questions about Vitamin D for primary care practice.
-
Mepolizumab Injection (Nucala)
Mepolizumab is indicated for add-on maintenance treatment of adult patients ≥ 12 years of age with severe asthma and with an eosinophilic phenotype.
-
Carotid Occlusion Rarely Develops from Asymptomatic Carotid Artery Stenosis
Recent study indicates that the risk of progression to carotid occlusion is well below the risk of carotid stenting or carotid endarterectomy.
-
Utility of Non-traditional Risk Factors in Patients Ineligible for Statin Therapy
Adding additional risk factors not in the pooled risk equation to low-risk subjects identified a sub-group with an observed event rate > 7.5% who may warrant statin therapy.
-
Effect of Modified Valsalva Maneuver for Emergency Treatment of Supraventricular Tachycardia
In patients presenting with supraventricular tachycardia, a modified Valsalva maneuver with leg elevation and supine positioning at the end of strain was demonstrated to be more effective than the standard Valsalva maneuver at restoring normal sinus rhythm.
-
Ceftazidime-avibactam — Formulary Considerations
Ceftazidime-avibactam is a new beta-lactam/beta-lactamase inhibitor combination approved for the treatment of complicated intra-abdominal infections in combination with metronidazole, and complicated urinary tract infections, including pyelonephritis in patients with limited alternative treatment options.
-
Idarucizumab Injection (Praxbind)
The FDA has approved the first reversal agent for a direct oral anticoagulant. Idarucizumab is a humanized monoclonal antibody fragment derived from an IgG1 isotype molecule. -
Optimal Beta-blocker Dose Post-MI
Beta-blocker therapy after acute myocardial infarction was retired as a hospital performance measure because its almost universal acceptance removed its discriminating value. However, it is well known that clinically used doses are significantly lower than those achieved in the randomized trials, establishing their mortality-reducing benefits.
-
Can We Safely Discharge Patients on the Weekend?
ABSTRACT & COMMENTARY: The link between weekend discharge and 30- and 90-day readmission rates.